the mechanisms of action may interact in unpredictable ways
Another exciting avenue is the development of small-molecule GLP-1RAs, designed for oral delivery
Viking Therapeutics Sector: Dual and triple agonists for obesity, metabolic, and liver disease HQ: San Diego, CA Year Founded: 2012 Origin Story: The company built its pipeline around small molecule and peptide candidates licensed from academic and pharma sources, eventually advancing VK2735, a dual GLP-1/GIP receptor agonist designed to be the first such therapy available in both oral and injectable formulations
It is typically administered via small subcutaneous injections with dose adjustments made gradually based on tolerance and response
Symptoms like nausea, bloating, and constipation are most common during the initiation phase
GeoPharma gained notoriety in 2004 when it issued a press release misleadingly claiming FDA approval for a new prescription product to treat the side effects of chemotherapy and radiation